This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Outcomes assessed in the review
The health outcomes assessed in the review were: the annual incidence of dialysis and the annual number of kidney transplants; the average age of death for dialysis patients and of rejection for transplant patients; the lost duration of life at onset; the expected duration; the lost duration of life at death and at rejection for dialysis and transplant patients (i.e. years of life lost due to disability for morbidity and mortality).
All these health outcomes were reported for both dialysis and renal transplant patients by groups of age (as stated in the 'Study Population' section). Some of these effectiveness outcomes were included in the Weibull model in order to estimate the expected durations.
Study designs and other criteria for inclusion in the review
The studies included in the review seemed to be statistical data studies of the Japanese situation in terms of ESRD and its survival rates.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
At least 4 studies were included in the review.
Methods of combining primary studies
Not reported, although a narrative method seems to have been used.
Investigation of differences between primary studies
Results of the review
The annual incidence of dialysis in each age group was 25 patients (0 -9 age group), 118 patients (10 -19), 606 patients (20 -29), 1,201 patients (30 -39), 3,163 patients (40 -49), 5,587 patients (50 -59), 7,416 patients (60 -69), 5,389 patients (70 -79) , 2,032 patients (80 -89), and 92 patients (90 or older).
The annual number of LRD kidney transplants in each age group was 11 patients (0 -9 age group), 49 patients (10 -19) , 131 patients (20 -29), 160 patients (30 -39), 59 patients (40 -49), and 22 patients (50 or older).
The annual number of CAD kidney transplants in each age group was 2 patients (0 -9 age group), 4 patients (10 -19), 26 patients (20 -29), 71 patients (30 -39), 58 patients (40 -49), and 11 patients (50 or older).
For dialysis patients, the lost duration of life at death in each age group was 26.9 years (0 -9 age group), 21.3 years (10 -19), 17.8 years (20 -29), 19.6 years (30 -39) For CAD transplant patients, the lost duration of life at rejection in each age group was 65.9 years (0 -9 age group), 50.5 years (10 -19), 43.1 years (20 -29), 33.6 years (30 -39), 26.6 years (40 -49), and 16.6 years (50 or older).
Methods used to derive estimates of effectiveness
The author's assumptions were used to derive estimates of the age distribution of kidney transplant patients in 1995.
Estimates of effectiveness and key assumptions
The author assumed that the age distribution for kidney transplant patients in 1995 was the same as that of patients between 1983 and 1994. It was also assumed that, for each age group, the average age of onset was equal to the midpoint of each age group.
Therefore, according to the age group of the dialysis patients, the average age of onset was 5 (0 -9 age group), 15 ( 
Measure of benefits used in the economic analysis
The measure of benefit used in the economic analysis was the number of disability-adjusted life-years (DALYs) averted by treatment. DALYs were estimated according to the formulae proposed by Murray and Lopez (see Other Publications of Related Interest). The numbers of DALYs averted by treatment were estimated as the difference between the DALYs without treatment (assuming that ESRD patients would die just after the onset of the illness) and the DALYs with treatment. A lifetime horizon was considered for the economic analysis. Disability weights were derived from experts' opinions, on the basis of questionnaires that used the Person Trade-Off method. A total of 95 doctors involved in health-related policymaking participated. The median disability weights obtained were 0.231 for dialysis patients and 0.100 for transplant patients. Total effectiveness was estimated as the total number of DALYs averted in each one of the age groups, considering the annual incidence of dialysis and transplant patients.
Direct costs
The resource quantities and the costs were not reported separately. The direct costs included in the economic analysis may have been either those of the hospital or those of the health service. The direct costs of dialysis included both inpatient and outpatient medical costs, with the proportions of inpatient and outpatient dialysis being considered in calculating the total cost. The direct costs of kidney transplant also included inpatient and outpatient medical costs. However, in addition, the CAD kidney transplantation included the costs for the kidney transplant information system. The source of the direct cost data was the average health insurance payments for ESRD treatments provided by the National Sakura Hospital. Therefore, the costs were estimated from actual data. Discounting was performed using a 3% discount rate, and was relevant since the period considered was the lifetime of ESRD patients. It was not clearly established whether the price year was April 1996, or if this date related only to medical expenditures for dialysis.
Indirect Costs
No indirect costs were reported.
Currency
Japanese yen (Y).
Sensitivity analysis
Sensitivity analyses were carried out to investigate variability in the data. The parameters varied were the discount rate, age weights and disability weights. One-way sensitivity analyses were used. Discounting of the benefits at a 3% discount rate was also performed.
Estimated benefits used in the economic analysis
For the dialysis patients, the total number of DALYs averted for each age group was 624 (0 -9 age group), 3,023 (10-19), 13,620 (20 -29), 20,109 (30 -39), 34,911 (40 -49), 34,433 DALYs (50 -59), 23,144 (60 -69), 7,321 (70 -79), 825 (80 -89), and 8 (90 or older).
The number per patient in each age group was also reported in the paper.
The total number of DALYs averted in the dialysis group was 138,019.
For the LRD transplant patients, the total number of DALYs averted for each age group was 177 (0 -9 age group), 1,131 (10 -19), 1,465 (20 -29), 2,233 (30 -39), 536 (40 -49), and 198 (50 or older) .
The number per patient in each age group was also reported.
The total number of DALYs averted in the LRD transplant group was 5,740.
For the CAD transplant patients, the total number of DALYs averted for each age group was 12 (0 -9 age group), 67 (10 -19), 352 (20 -29), 865 (30 -39), 510 (40 -49) , and 86 (50 or older).
The total number of DALYs averted in the CAD transplant group was 1,892.
Cost results
For dialysis patients, the cost per patient in each age group was Y156,355 (0 -9 age group), Y151,523 (10 -19) , Y142,357 (20 -29) , Y116,052 (30 -39), Y87,700 (40 -49), Y58,697 (50 -59), Y38,865 (60 -69), Y25,963 (70 -79), Y17,369 (80 -89) , and Y14,322 (90 or older).
The total cost for the dialysis group was Y1,317,521,706.
For LRD transplant patients, the cost per patient in each age group was Y30,537 (0 -9 age group), Y35,240 (10 -19) , Y18,668 (20 -29) , Y25,550 (30 -39) , Y20,437 (40 -49) , and Y26,277 (50 or older).
The total cost for the LRD transplant group was Y10,381,779.
For CAD transplant patients, the cost per patient in each age group was Y21,985 (0 -9 age group), Y29,146 (10 -19) , Y26,363 (20 -29) , Y26,455 (30 -39) , Y23,718 (40 -49) , and Y26,401 (50 or older).
The total cost for the CAD transplant group was Y4,392,173. 
Synthesis of costs and benefits
The cost-effectiveness ratios (CERs) by age groups were calculated for each one of the alternatives, as the cost per DALY averted. The author also estimated CERs for the overall interventions.
For dialysis patients, the CERs (cost per DALY averted) were Y6,259 (0 -9 age group), Y5,915 (10 -19) , Y6,334 (20 -29) , Y6,931 (30 -39) , Y7,946 (40 -49) , Y9,524 (50 -59) , Y12,453 (60 -69) , Y19,112 (70 -79) , Y42,755 (80 -89) , and Y170,834 (90 or older).
The CER for dialysis, in general, was Y9,546 per DALY averted.
For LRD transplant patients, the CERs (cost per DALY averted) were Y1,851 (0 -9 age group), Y1,537 (10 -19) , Y1,675 (20 -29) , Y1,831 (30 -39) , Y2,232 (40 -49) , and Y2,913 (50 or older).
The CER for LRD transplantation, in general, was Y1,809 per DALY averted.
For CAD transplant patients, the CERs (cost per DALY averted) were Y2,992 (0 -9 age group), Y1,852 (10 -19) , Y1,932 (20 -29) , Y2,174 (30 -39) , Y2,706 (40 -49) , and Y3,399 (50 or older).
The CER for LRD transplantation, in general, was Y2,322 per DALY averted.
The results show that the CERs by age groups were 3 to 4 times higher for dialysis patients than for the transplantation patients. The sensitivity analyses showed that there was no effect in the order of the magnitudes of the CERs among dialysis, LRD transplants and CAD transplants, although the values of the CER varied considerably with age weights.
Validity of estimate of measure of effectiveness
The author did not report that a systematic review was undertaken. In addition, the effectiveness analysis appears to have been based on statistical data of practical treatments. The author reported that this might have been a limitation for the effectiveness results, as matching the patients among treatments was not considered. Differences among the patients could have affected the results, although the differences in CERs were sufficiently large to suggest that they were probably not due solely to differences in the patients' characteristics. In order to calculate survival rates by means of modelling, the author assumed that those transplant patients with a rejected organ would die just after the rejection. This assumption does not seem to be realistic although, as the author stated, it was taken in order to avoid overestimation of the survival for those patients who would benefit from dialysis in a normal situation. The Weibull model was used to estimate survival. This model does not reflect the effect of ageing. The author adjusted to correct for this error and suggested that the validity of this modification should be inspected more vigilantly.
Validity of estimate of measure of benefit
The estimation of benefits was based on methodology proposed by the World Health Organisation. The choice of the DALYs as the summary measure of benefit was justified, as stated by the author. DALYs include the patients' quality of life in addition to mortality aspects of disease. The disability weights were derived from a questionnaire answered by experts. The Person Trade-Off method was used although, as reported, this method may contain ethical problems that would never be accepted by some people.
